neurobid.eu

Created in 1964, Inserm is a public institution with a scientific and technical vocation, under the dual auspices of the Ministry of Health and the Ministry of Higher Education and Research. Inserm iis the only French public research body entirely dedicated to human health. Its researchers are committed to studying all diseases, whether common or rare, through their research in the fields of biology, medicine and public health.

Two Inserm laboratories will be involved in NEUROBID: UMR-842 neuro-oncology / neuroinflammatory diseases and UMR-676 perinatal brain damage. The main objective of these teams is to establish the roles of blood-brain barriers in the pathophysiology and pharmacology of CNS diseases as well as to design neuroprotective strategies.

Within the present project, the UMR-842 is more specifically in charge of the investigations on neuroprotective functions of the blood-CSF barrier in health and diseases and related drug targeting strategies during brain development, while UMR-676 will focus on providing relevant models for perinatal and adult brain damage as well as testing protective drugs.

Jean-François Ghersi-Egea This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Jean-François Ghersi-Egea is pioneer in the original discovery of the blood-CSF barrier as a detoxifying site for the brain by coupled metabolic-efflux processes. His team will contribute its expertise to the tasks related to developmental regulation and pharmacological manipulation of drug transport and other barrier properties at the blood-CSF interface in normal condition and following inflammation exposure. They will analyse the antioxidant and other detoxifying properties of the choroidal tissue in the different disease models developed by the partners.

Pierre Gressens This e-mail address is being protected from spambots. You need JavaScript enabled to view it

The team of Pierre Gressens will be NEUROBID’s stronghold in the area of perinatal excitotoxic and combined excitotoxic/inflammatorybrain injury and related intervention. They will contribute their experimental models (in vivo white matter lesions induced by excitotoxins in postnatal day P0, P2, P5, P10, P15, P20, P40, or P60 mice, inflammatory cytokines or LPS in P1 to P5, P5 to P10 or P56 to P60 mice) and expertise (physiopathology, pharmacology, cellular and molecular biology, small animal MRI and neuroprotection) to all relevant aspects and experiments of NEUROBID.

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
(INSERM)

www.inserm.fr